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Abstract 
Introduction: To evaluate systematically randomised clinical trials investigating non-opioid medications for 
the management and treatment of chronic breathlessness.    
Areas Covered: The evidence for the role of benzodiazepines, anxiolytics, selective serotonin re-uptake 
inhibitors (SSRIs), tricyclic antidepressants, antihistamines, cannabinoids, nebulized furosemide and herbal-
based treatments were critically reviewed. Search of the Clinical Trials Registry (Clinicaltrial.gov) identified 
ongoing studies expected to generate new data in the near future in several classes of non-opioid 
medications for their net effect on chronic breathlessness. 
Expert Commentary:  Morphine still has the best levels of evidence for the symptomatic treatment of 
chronic breathlessness. Non-opioid treatments for chronic breathlessness are less studied than morphine 
and morphine-related medications although evidence is emerging in relation to some options. Currently, 
there is insufficient evidence to recommend non-opioids in the routine treatment of chronic 
breathlessness. There is a need to find agents, new as well as re-purposed, that can be used as alternative 
therapies to opioids for chronic breathlessness for people who are unable to tolerate morphine. 
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1.0 INTRODUCTION 
 
Chronic breathlessness is a core issue for all physician and other health professionals involved in the care of 
people with a variety of advanced medical conditions. Despite optimal treatment of the underlying 
pathologies, the multidimensional experience 1 of distressing chronic breathlessness remains a major 
problem for patients, their family caregivers and clinicians, often leaving all feeling helpless.  
Neuroimaging studies have shown the central pathways involved in response to breathlessness include 
several limbic, paralimbic and cerebellar loci.2 3 4 5This, along with a growing understanding of the role of 
endogenous opioids6 7 and serotonin8 in breathing, and the relationship between breathlessness and 
anxiety and depression9 10, has led to calls to find ways to modulate central neural activity in relation to 
breathlessness and thus alleviate the unpleasantness, intensity, and emotional and functional responses to 
breathlessness. 11 12 13 A range of potential drug intervention candidates aiming to modulate central 
perception have been investigated. This systematic review summarises the evidence so far and discusses 
the implications for current clinical practice, and for future research. 
 
2.0 IDENTIFICATION OF LITERATURE 
To identify potential studies we searched MEDLINE, EMBASE, Google Scholar for randomised controlled 
trials investigating the role of potential non-opioid medications for the relief of chronic breathlessness due 
to medical conditions. We included studies where chronic breathlessness due to medical conditions was 
measured as a primary or secondary outcome. Clinical trials and relevant retrospective and prospective 
observational studies (especially if trials were few or lacking) exploring the role of a specific drug-classes 
were included. The reference lists of studies identified and relevant reviews were hand-searched. We also 
searched registers of clinical trials for further ongoing or unpublished studies, up to November 2016.  
List of terms and words used for the systematic search and review of published clinical trials: “dyspnea” , 
“dyspnoea”, “breathlessness”, “symptom”, “drug”, “agent”, “benzodiazepines”, “anxiolytic”, “anti-
histamines”, “SSRI”, “selective serotonin reuptake inhibitor”, “tricyclic antidepressant”, “anti-histamine”, 
“nebulized furosemide”, “inhaled furosemide”, “herbs”, “herbal”, “cannabis”, “tetrahydrocannabinol”. 
Steroids were not included as they most likely mediate any effect on breathlessness indirectly through their 
anti-inflammatory actions on the underlying disease process rather than directly modifying the perception 
(e.g. asthma, peritumour oedema in lymphangitis carcinomatosis). Antihistamines were included because 
they also have central sedative effects. 
One researcher (CB) screened titles, abstracts, retrieved papers and extracted data. Uncertainty regarding 
inclusion was resolved by discussion with MJ. 
 
3.0 FINDINGS 
The findings are presented by drug class.  
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3.1 Anxiolytics  
3.1.1. Benzodiazepines 
Anxiolytics, such as benzodiazepines, are commonly used to help to reduce chronic breathlessness in 
palliative care settings. The need for robust placebo-controlled safety data regarding benzodiazepines is 
illustrated by recent observational studies. A population registry-based, longitudinal, consecutive cohort 
study on 2249 people with severe COPD on long term oxygen found that benzodiazepines and low dose 
oral morphine (≥30mg morphine equivalent daily dose) were not associated with increased hospital 
admission, but benzodiazepines ( but not low dose morphine) were associated with increased mortality in a 
dose-related manner.14 A risk of increased respiratory adverse events due to use of benzodiazepines in 
people with COPD was also highlighted by Vozoris et al in a large cohort study. In benzodiazepine-naïve 
people with COPD a new prescription of benzodiazepines was linked to an increased rate of outpatient 
respiratory exacerbations (RR 1.45 CI 1.36-1.54) compared to non-users.15  
A pilot phase I open label trial evaluated the role of oral clonazepam 0.5 nocte and 10 mg oral sustained 
release morphine, administered for at least 4 days, in 11 people with COPD and chronic breathlessness 
(modified Medical Research Council dyspnoea scale [mMRC] > 2). (Table 1) Despite the study’s limitations, a 
positive effect of clonazepam in reducing breathlessness by 15% over baseline was found, indicating the 
need for further study.16 A retrospective analysis of 115 clinical records in a population of people with 
cancer, heart failure or COPD suggested that patients receiving opioids and benzodiazepines showed 
greater improvement of breathlessness compared to those receiving only opioids or benzodiazepines.17 
Midazolam was also used in a palliative sedation protocol18 in 4 people in the last hours or days of life with 
cancer and severe breathlessness, and was reported to be effective.  
The safety of lorazepam 1 mg sublingually in addition to opioids was evaluated in a prospective non-
randomised study of 26 patients admitted to a palliative care unit with chronic breathlessness and anxiety. 
Lorazepam combined with opioids appeared to be safe and effective in relieving breathlessness and anxiety 
in the palliative care setting since no clinically important variations of SpO2 and pCO2 were recorded. 
Breathlessness and anxiety were recorded and monitored with a 0-10 numeric rating scale (NRS) however; 
sedated patients might not have been able to distinguish between the two sensations. This might explain 
the similar scores and the very strong relationship observed between chronic breathlessness and anxiety 
(r= 0.952, p< 0.0001).19 
3.1.1.1. Randomised controlled trials 
A recently updated Cochrane review20  of a range of benzodiazepines (diazepam, midazolam, alprazolam, 
lorazepam) showed no evidence of a net benefit on chronic breathlessness in people with cancer or COPD 
when compared to placebo. The review concluded that any use of benzodiazepines for chronic 
breathlessness should be as a second or third-line treatment within a carefully monitored individual 
therapeutic trial.  Route of administration was not significant in sensitivity analysis. The pressing need is for 
adequately powered, randomised controlled trials in order to inform clinicians in everyday practice rather 
than further phase II studies or case series.  
 
3.1.2 Buspirone 
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Buspirone, an azapirone which does not suppress respiration used in the management of generalized 
anxiety disorders, has been suggested as a potential modulator of chronic breathlessness. Small, 
underpowered trials have given mixed results,21 22 however, a recent phase III clinical trial in people with 
cancer and chronic breathlessness showed no improvement in breathlessness.23  This large study showed 
no sign of benefit and whether it should be repeated in patients other than those with cancer remains open 
to discussion.  
3.1.3 Ondansetron 
Ondansetron is a serotonin antagonist, commonly used to treat chemotherapy-induced emesis. It is also 
considered to have a possible anxiolytic and anti-psychotic effect.24 25 26 Exploratory work investigated its 
potential role as a modulator of chronic breathlessness working on the insular cortex in a small RCT (n=10) , 
but showed no benefit in healthy volunteers with experimentally induced acute breathlessness.27 A study of 
inhaled ondansetron (8 mg) compared to inhaled 0.9% saline in healthy subjects in whom acute 
breathlessness was induced by thoracic constriction and exercise [NCT01851993] is ongoing. It is not known 
how such findings will apply to the context chronic breathlessness. 
3.2 Antidepressants 
3.2.1 The epidemiology of chronic breathlessness and depression 
Antidepressants such as selective serotonin re-uptake inhibitors (SSRIs) and tricyclic antidepressants have 
been studied for their potential role in reducing chronic breathlessness. 28  A pathophysiological link 
between respiratory and psychiatric symptoms could be found at the level of serotonergic system and its 
effect on the modulation of central respiratory control and sensitivity to carbon dioxide. A cross sectional 
study of 836 people with COPD estimated the prevalence of depression and related symptoms.29  About 
three quarters of this large unselected population of COPD patients had depression; this was moderate or 
severe in half (51.5%). Depression was associated with a poorer quality of life (QoL), increased rates of 
exacerbations and higher prevalence of comorbidities. Breathlessness prevalence was associated 
significantly in people with COPD and depression. Another cross-sectional observational study of 54 people 
with COPD explored the relationship between anxiety, depression, breathlessness and thoraco-abdominal 
mechanics at rest and/or during exercise. Anxiety and depression were associated with poorer clinical 
disease control and depressive symptoms were associated with breathlessness, independent of breathing 
pattern and thoraco-abdominal mechanics.30  
3.2.2 Randomised controlled trials 
Exploratory studies of people with COPD are limited by the small sample sizes and underlying 
methodologies used.19 31-36  These provide preliminary support to further explore a role for these drugs in 
reducing anxiety and chronic breathlessness, and improving quality of life. However, a Cochrane Review in 
2011 failed to demonstrate conclusive evidence for SSRI and tricyclic antidepressants in managing 
breathlessness, despite improvement in anxiety, quality of life and exercise tolerance with paroxetine 20 
mg/daily.37 A randomised trial of 138 patients with COPD and major depression compared a Personal 
Intervention (PID-COPD) against usual care over 28 weeks; findings showed that PID-COPD led to an 
interacting spiral of improvement, improved adherence with antidepressant treatment and COPD 
rehabilitation, and reduced breathlessness-related disability. However, in this complex intervention there 
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were different factors and drugs used and evaluation of particular sub-classes of antidepressants was not 
possible.38 An RCT of people with COPD and depression found that those allocated to fluoxetine 25 mg / 
daily in addition to usual care compared with usual care only had improvement in breathlessness scale 
scores, oxygenation and spirometry.39  
Dale et al. (2012) enrolled 36 people with cancer in a cross over, double blind randomised trial to evaluate 
mirtazapine (15mg vs 30 mg), showing improvement of many cancer related symptoms and QoL.40  A phase 
II trial is ongoing to test the feasibility of a phase III trial to evaluate mirtazapine for the management of 
chronic breathlessness due to a variety of optimally treated medical conditions.[Eudract number 2015-
004064-11]  
Phase III  RCTs are required to give definitive evidence of these agents for the treatment of breathlessness; 
one is due to report early 2017 (ACTRN12610000464066; sertraline for chronic breathlessness).41 A safety 
trial in people with COPD undergoing pulmonary rehabilitation is underway ([NCT02813447]; primary 
outcomes of breathlessness scores, quality of life and exercise tolerance measures will be primary 
outcomes. 
 
3.3 Antihistamines   
Antihistamine agents (anti-H1) have been investigated alone or in association with benzodiazepines or 
morphine to reduce breathlessness. These drugs have anti-muscarinic and anti-serotonergic activity leading 
to sedative and antipsychotics effects.42 Promethazine has been investigated in different settings to 
evaluate a potential role in breathlessness management and as an opioid-sparing treatment.  
Six healthy volunteers took promethazine 25 mg orally before a treadmill test and reported reduced effort-
induced acute breathlessness (VAS) although this did not reach statistical significance. 43The finding was not 
confirmed in another study of 12 healthy subjects.44 In this study, half also received chlorpromazine; these 
participants had a statistically significant improvement in acute breathlessness scores (mean relative 
reduction 19.3%), with no evidence of respiratory depression. The application of these findings to the 
clinical setting of chronic breathlessness has not been studied at this time.  
An evaluation of the effect of 125mg promethazine daily for two weeks in 15 men with COPD (“pink puffer” 
phenotype) showed a reduction in breathlessness scores and improved exercise tolerance.45  However, 
promethazine 100 mg daily given to 11 people with COPD showed no improvement in breathlessness at 1 
month.46  An evaluation of 25 mg promethazine together with morphine 30 mg administered before 
exercise in 7 men with COPD gave improved exercise tolerance and increased maximum minute ventilation, 
but showed no differences in perceived breathlessness (Borg scale).47These findings cannot be applied to 
clinical practice at this time.  
3.4 Cannabinoids 
Cannabis and cannabis-related molecules have been investigated to evaluate their potential role in the 
treatment of several symptoms in a wide sub-set of patients. A recent meta-analysis, conducted according 
to Cochrane criteria, highlighted both the potential benefit and appreciable risks of these drugs.48 
Cannabinoids have been studied by Pickering et al. as a potential treatment for breathlessness in a small (9 
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patients, 4 with moderate COPD) RCT comparing the effect of cannabis-based medicinal extract with 
placebo in reducing acutely induced breathlessness. Results showed no changes on VAS measurements 
although COPD patients used fewer "breathlessness" descriptors.  Participants reported adverse events 
(intoxication and reversible cardiac dysrhythmias).49 Therefore current evidence does not support the use 
of acutely administered cannabinoids for breathlessness.  
 
3.5 Nebulized furosemide 
Animal models suggest a potential role for furosemide in changing local chloride ion channels and its 
negative effect on c-fibers receptor and vagal irritant receptors, and an associated positive effect on 
alveolar stretch receptors.50 Nebulised inhaled furosemide (NIF) has been tested in acute breathlessness 
induced in healthy volunteers and in people with acute asthma51, COPD52 53 54 , heart failure55 and lung 
cancer.56-59  
3.5.1 NIF in experimental settings 
Three studies tested NIF 40 mg compared to 0.9% saline in 32 subjects (respectively n=12, n=10, n=10) 
evaluating its role in reducing breathlessness and air hunger during experimental conditions (loaded 
breathing test, breath holding, CO2 chemosensitivity measured by the steady-state and rebreathing 
methods, hypercapnia during constrained ventilation) in double blind randomised cross over trials.60 61 62 
Findings showed a reduction in breathlessness which was not correlated with the ventilator drive of CO2. 
NIF 40 mg, 80 mg or normal saline in 9 healthy subjects found no benefit from NIF in alleviating respiratory 
effort during flow limited exercise.63   
3.5.2 NIF and COPD 
NIF 40 mg was compared to 0.9% saline in two studies in 19 52 and 20 53 people with COPD respectively 
undergoing exercise tests (incremental exercise, symptom limited exercise) to induce breathlessness. Both 
trials showed a reduction in breathlessness intensity, increased exercise endurance and optimisation of 
lung volumes, with an improvement in SpO2 levels rather than a diuretic effect. NIF 40 mg compared to 
0.9% saline in 100 people with exacerbations of COPD admitted to an emergency department showed that 
those allocated to NIF had a statistically significant improvement in Borg scores, spirometry, blood gases, 
heart and respiratory rate, and blood pressure. All subjects also inhaled salbutamol and ipratropium, and 
received intravenous hydrocortisone.58  These data suggest that a trial of NIF 40 mg to reduce chronic 
breathlessness in COPD exacerbations is safe, while further work is needed to evaluate its role in relieving 
chronic breathlessness. Cardiovascular co-morbidities are frequent in people with moderate or severe 
COPD. None of these studies noted this comorbidity so work is needed to evaluate the effect of NIF on 
chronic breathlessness as a result of cardiac failure. Recently NIF was compared to normal saline in people 
with stable advanced heart failure (32 patients) undergoing right heart catheterisation. No difference were 
observed in haemodynamic parameters in the one hour  after administration of the drug, but a diuretic 
effect was seen in those allocated to NIF.59 Breathlessness was not measured in this study. Further research 
is warranted.      
3.5.3 NIF and cancer 
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NIF has been tested to reduce chronic breathlessness in people with lung cancer. Studies are small and 
have found mixed results.60 61 62 63   
All these studies have used nebulised saline as the control arm and used either jet or ultra-sonic nebulizers. 
It is important to note that nebulised saline, administered via an efficient nebulizer, improved 
breathlessness scores and sputum clearance in people with COPD and therefore may have a role in its own 
right in the relief of breathlessness, and makes the interpretation of studies of nebulised agents more 
challenging.64  
Currently two clinical trials of nebulised furosemide to reduce chronic breathlessness are registered as 
open. NCT01851980 will investigate the role of NIF on Physical Activity-Related Breathlessness in a human 
model of exercise-induced breathlessness (primary outcome: intensity of breathlessness on a Borg 0-10 
scale); and NCT02524054 aims to evaluate NIF in patients with refractory breathlessness (primary outcome: 
intensity of breathlessness on a VAS).  Results are expected during 2017.  
3.6 Herbal based treatments 
Herbal based treatments such as Bu-Fei Jian-Pi granules, Bu-Fei Yi-Shen granules and Yi-Qi Zi-Shen granules 
in addition to standard GOLD guideline COPD therapy have shown reduction in breathlessness in an open-
label RCT of 352 people with COPD. 66 Further, a secondary sub-set analysis on 136 patients older than 65 
years old, saw the same result. 65 These different kinds of granules have been administered to specific 
patient clusters, according to the traditional Chinese medicine.  Further research based on designed 
placebo controlled RCT in breathlessness patients, alongside systematic documentation of toxicities is 
therefore advised. 
 
4.0 CONCLUSIONS 
Extended release morphine remains the most studied symptomatic treatment for chronic breathlessness. 
There is an urgent continuing need to explore other therapeutic interventions. Such studies are, in part, 
based on the emerging knowledge of the central pathways and receptors involved in the perception and 
modulation of the perception of chronic breathlessness.  
This review summarises the current evidence for currently available agents with regard to potential 
repurposing for the management of breathlessness. None have more than preliminary evidence to support 
their use and some have evidence to show they have no role. Further work is required for those with 
potential. It is not possible currently to make recommendations with regard to which drug for which 
person. There is also a need to identify new agents specifically developed to interact with the perception of 
breathlessness safely.   
 
5.0 EXPERT COMMENTARY 
Chronic breathlessness due to medical conditions has a serious impact on the daily experience of those 
who live with it, their family and friends and the health and social care professionals.67 68 It is more strongly 
associated with survival than surrogate markers of lung function,69 and people with chronic breathlessness 
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are more likely to have poor quality of life,70 anxiety and depression,71 and increased health service 
utilisation especially emergency services.72 Breathlessness, in a traditional medical model, views the 
symptom largely as a diagnostic signpost, with the focus of management thereafter being interventions for 
the causative medical condition. However, despite optimum disease-directed treatment, breathlessness 
will persist for many, especially as the disease advances. There are evidence-based treatments for chronic 
breathlessness itself, particularly based on non-pharmacological interventions which remain the bedrock of 
breathlessness management. However, they are not implemented systematically into clinical practice partly 
due to lack of clinician education and partly due to lack of resources. Further, patients may persist with 
troublesome chronic breathlessness despite such measures, in which case, pharmacological approaches 
may be of use. Recourse to pharmacological measures may be needed sooner in people with a rapid 
decline, than those with a more stable trajectory. The evidence base for pharmacological interventions is 
growing, but is strongest for oral low-dose morphine. However, not all patients will tolerate morphine and 
other pharmacological approaches are needed. 
There are a number of published clinical trials of mainly preliminary evaluation of a range of medications 
which have a biologically plausible rationale for re-purposing for breathlessness management. These 
include anxiolyotics, antidepressants, antihistamines, cannabinoids and nebulised furosemide. Only one 
adequately powered trial of an anxiolytic has been reported so far (buspirone vs placebo in people with 
breathlessness due to cancer) which demonstrated no benefit. This trial, however, shows the importance of 
trials which recruit to their a priori sample size as previous phase II work had indicated benefit. A phase III 
trial for sertraline is due to report in 2017. However, much of the other work has failed to show promise, or 
has been inconclusive. The exception perhaps is nebulised medication such as furosemide and normal 
saline where further study seems to be warranted.  The ultimate goal in this field is to be able to offer 
patients tailored pharmacological interventions to benefit chronic breathlessness thereby improving 
functional ability, quality of life and levels of independence. 
Future work requires well designed trials with adequate power to test the effectiveness of both re-
purposed drugs and also newly developed compounds. Therefore greater understanding of the 
pathophysiological pathways of the genesis and perception of chronic breathlessness itself is needed to 
inform potential targets for new interventions. A better understanding of whether benefits seen for 
breathlessness in one medical condition are replicated in another. For example, is the improvement in 
breathlessness with nebulised normal saline in people with COPD mediated through improved mucous 
clearance and if so, does this mean that the benefit would not be seen in patients with interstitial lung 
fibrosis? Another challenge is the need to understand how health service provision for such patients should 
be best provided in order to implement interventions directed at both the underlying disease and the 
ongoing symptom in an integrated manner. 
Current developing areas of research include work to understand the pathways of central perception of 
chronic breathlessness, the effectiveness and implementation of complex interventions for breathlessness 
in different settings, and systematic testing of medications to improve this previously neglected symptom.  
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6.0 FIVE-YEAR VIEW 
With regard to non-opioid medication for the management of chronic breathlessness, we anticipate that in 
five years, research with selective serotonin reuptake inhibitors (SSRI) and serontonin and noradrenaline 
inhibitors (SNRI) will be defined for their net effect on chronic breathlessness. We should have a clearer 
understanding of the role of nebulised furosemide. We hope that multi-disciplinary breathlessness 
assessment and management as a specific focus  alongside ongoing optimisation of the underlying cause(s) 
will become a routine part of clinical practice.  
 
 
7.0 KEY ISSUES 
• Morphine has the best levels of evidence for the symptomatic treatment of chronic breathlessness.  
• Non-opioid treatments for chronic breathlessness are less studied than morphine and morphine-
related medications although evidence is emerging in relation to some options. In particular there 
is evidence that buspirone is ineffective in people with cancer and nebulized normal saline is 
helpful in people with COPD. 
• Currently, there is insufficient evidence to recommend non-opioids in the routine treatment of 
chronic breathlessness. Results from a phase III trial of sertraline vs placebo in people with chronic 
breathlessness due to a variety of causes will report in 2017. 
• There is a need to find agents, new as well as re-purposed, that can be used as alternative 
therapies to opioids for chronic breathlessness for people who are unable to tolerate morphine. 
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Table 1: Benzodiazepines for breathlessness. Reproduced with permission of the European Respiratory Society © 
First 
Author, 
Year 
Study design Drug tested Patients 
enrolled 
Breathlessness 
measure 
Benefit perceived on acute-
induced Breathlessness (AIB) Vs 
Chronic Breathlessness (CB) 
Statistically significant 
benefit breathlessness 
Notes
Simon 
2016 20 
Cochrane 
systematic 
review 
alprazolam, diazepam, 
midazolam, lorazepam, 
clorazepate, temazepam 
COPD
Cancer  
 
VAS
Breathlessness 
grade scale 
Borg scale 
Multidimensional 
scales (SGRQ, CRQ) 
CB No Simon 2016 20 
Clemens 
2011 19 
Prospective,  
non 
randomised 
Oral lorazepam 1 mg and 
morphine as needed 
26 patients 
admitted to a 
palliative care 
unit 
Numeric scale (0-
10) 
CB No Safety* of co-
administration 
Allcroft 
2013 16 
Open label 
trial 
Oral clonazepam 0.5 mg 
nocte and morphine 
extended release 10 mg 
11 COPD with 
mMRC> 2 
CB 5 patients reported 
benefit 
Safety* of co-
administration 
Hardy 
2016 73  
Randomised, 
double 
blind, cross 
over trial 
Intranasal midazolam 62 between 
cancer, chronic 
heart failure, 
COPD 
0-10 breathlessness  
score,  HADS, 
Cancer dyspnoea 
scale 
CB
 
* safety was defined as effect of benzodiazepines on breathing, ventilation and gas exchanges. COPD – chronic obstructive pulmonary disease; VAS – Visual 
Analogic Scale; HADS - Hospital Anxiety and Depression Scale; RCT – Randomised clinical trial; mMRC – modified Medical Research Council breathlessness scale; 
BDZ – benzodiazepines; SGRQ - St. George’s Respiratory Questionnaire, CRQ - Chronic Respiratory Disease Questionnaire
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Table 2: Buspirone for breathlessness 
Buspirone 
First Author, 
Year 
Type of 
study 
Drug tested Patients 
enrolled 
Breathlessness 
measure 
Statistically 
significant 
benefit 
breathlessness 
Benefit perceived on 
acute-induced 
Breathlessness (AIB) 
Vs Chronic 
Breathlesness (CB) 
Argyropoulou 
1993 21 
RCT 20 mg 
Buspirone 
16 COPD BORG No AIB 
Singh, 1993 22 RCT 30-60 mg 
Buspirone  
11 COPD BORG No AIB and CB 
Peoples, 2015 
23 
RCT 10-20 mg 
Buspirone 
432 
Cancer 
OCD 
STAI-S 
No CB 
 
COPD – Chronic Obstructive pulmonary disease; OCD – Oxygen Cost diagram; STAI-S  State-Trait Anxiety 
Inventory 
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Table 3: Antidepressants for breathlessness 
Antidepressants, SSRI
First Author, 
Year 
Type of study Drug tested Patients 
enrolled 
Breathlessness 
measure 
Statistically 
significant 
benefit 
breathlessness 
Notes Benefit perceived on acute-induced
Breathlessness 
 (AIB) Vs  Chronic Breathlessness (CB) 
Gordon, 1985 
31 
RCT 25-100 mg 
despiramine 
13 COPD n.a. n.c. Poor 
compliance, 
adverse 
reactions 
CB
Light, 1986 32 RCT 105-128 mg 
doxepine 
12 COPD n.a. n.c. Improvemen
t in 12MWT 
AIB
Borson, 1992 
33 
RCT nortriptyline 30 COPD n.a. n.c. Improvemen
t in 
“respiratory 
symptoms” 
CB
Grove, 1995  
74 
RCT 60-90 mg 
mianserin 
12 COPD n.a. No The study 
was 
designed to 
identify 
difference 
from oral 
corticosteroi
ds 
AIB and CB
Dale  2002 40  Open label, 
cross-over RT 
15-30 mg 
mirtazapine 
36 
cancer 
n.a. n.c. Improvemen
t of cancer – 
related 
CB
19 
 
symptoms
LaCasse 2004 
35 
RCT 5-20 mg 
paroxetine 
23 COPD CRQ No Dyspnea not 
improved 
CB
Eiser 2005 36 RCT 20 mg 
paroxetine 
28 SGRQ Yes Reduce 
anxiety, 
improved 
effort 
tolerancean
d QoL, but 
only when 
administere
d for 3 
months 
CB
Alexopoulous 
2014 38 
RCT Any 
antidepressant 
138 
COPD 
DRDQ Yes - CB
Momtaz 2015 
39 
RCT 20 mg 
fluoxetine 
50 COPD BORG Yes - CB
 
COPD – chronic obstructive pulmonary disease; n.c. – not conclusive; n.a. – not available; QoL - Quality of Life; CRQ - Chronic respiratory questionnaire; SGRQ - 
St. George Respiratory questionnaire; DRDQ - Dyspnoea related disability questionnaire 
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Table 4: antihistamines for breathlessness 
Antihistamines 
First 
Author, 
Year 
Type of study Drug tested Patients 
enrolled 
Breathlessness 
measure 
Statistically 
significant 
benefit 
breathlessness 
Benefit perceived 
on acute-induced 
Breathlessness 
(AIB) Vs Chronic 
Breathlesness 
(CB) 
Stark 1981 
44 
RCT promethazine 6 healthy VAS Yes AIB
Woodcock 
1981 45 
RCT promethazine 15 COPD Likert scale Yes AIB
O’Neill 
1985 43 
RCT promethazine 
chlorpromazine 
12 healthy
6 healthy 
VAS
VAS 
No 
Yes 
AIB
Rice 1987 
46 
RCT promethazine 11 COPD Subjective 
dyspnoea rating 
No AIB, CB
Light 1996  
47 
RCT promethazine and 
morphine 
7 COPD BORG No AIB
 
COPD – Chronic Obstructive pulmonary disease; VAS – Visual Analogic Scale 
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Table 5: Nebulized Inhaled furosemide for breathlessness. Reproduced with permission of the European 
Respiratory Society © 
Nebulized Inhaled Furosemide  
First Author, 
Year 
Type of 
study 
Drug 
tested 
Patients 
enrolled 
Breathlessness 
measure 
Statistically 
significant 
benefit 
breathlessness 
Benefit perceived on 
acute-induced 
Breathlessness (AIB) Vs 
Chronic Breathlesness 
(CB) 
Nishino 2000 
60 
RCT 
crossover 
NIF 40 
mg 
12 healthy VAS Yes AIB 
Minowa 2002 
61 
RCT NIF 40 
mg 
10 healthy VAS Yes AIB 
Stone 2002 57 RCT 
crossover 
NIF 20 
mg 
7 lung cancer 
terminal 
VAS No CB 
Ong 2004 52 RCT 
crossover 
NIF 40 
mg 
19 COPD VAS Yes AIB 
Moosavi 2007 
62 
RCT 
crossover 
NIF 40 
mg 
10 healthy Effect on 
reduction of air 
hunger 
Yes AIB 
Laveneziana 
2008 63 
RCT NIF 40-
80 mg 
9 healthy BORG No AIB 
Jensen 2008 53 RCT 
crossover 
NIF 40 
mg 
20 COPD BORG Yes AIB 
Wilcock 2008 
59 
RCT  NIF 40 
mg 
15 cancer BORG No AIB 
Sheikh 
Motahar 
Vahedi  2013 
54 
RCT NIF 40 
mg 
100 COPD 
during 
exacerbation 
VAS Yes CB 
 
 
 
